Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

InMed becomes Mentari Therapeutics as migraine antibody pipeline takes centre stage

The completed merger gives the renamed US company a PACAP-targeting migraine prevention antibody in early clinical testing, with a bispecific follow-on heading towards a regulatory filing.

16 Nov 2026 · InMed Pharmaceuticals Inc. INM · Company news

InMed Pharmaceuticals Inc. has finished combining with Mentari Therapeutics and now trades under the Mentari Therapeutics, Inc. name. The deal completed on 6 November 2026, according to the management's discussion and analysis the company filed with its Form 8-K.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →